Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Appointed director

Avenir Wellness Solutions, Inc. (CURR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity"
04/20/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
03/08/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Employment Agreement, by and between Avenir Wellness Solutions, Inc. and Nancy Duitch"
01/17/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Certificate of Amendment of Certificate of Incorporation",
"CURE Pharmaceutical Unveils Exciting New Brand Identity with Name Change to Avenir Wellness Solutions, Inc."
08/19/2022 8-K Quarterly results
07/28/2022 8-K Quarterly results
01/07/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Forbearance Agreement"
12/03/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
01/06/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue™ OXNARD, Calif.- Jan. 5, 2021 -- CURE Pharmaceutical Holding Corp , a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration has approved an Investigational New Drug application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate for the treatment of erectile dysfunction . CURE is seeking approval of this product via the 505 regulatory pathway to expedite the U.S. approval process. CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfi..."
12/15/2020 8-K/A Financial Statements and Exhibits
Docs: "Unaudited Condensed Financial Statements of The Sera Labs, Inc. for the nine months ended September 30, 2020 and Audited Financial Statements of The Sera Labs, Inc. for the year ended December 31, 2019",
"Unaudited Pro Forma Combined Financial Statements of Cure Pharmaceutical Holding Corp. as of and for the nine months ended September 30, 2020, and as of and for the year ended December 31, 2019"
12/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "About SeraLabs SeraLabs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. SeraLabs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names SeraRelief™, Seratopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™. SeraLabs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, SeraLabs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level ..."
11/02/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Security Purchase Agreement",
"Series A Convertible Note",
"Series B Convertible Note",
"Note Purchase Agreement",
"Secured Promissory Note",
"Master Netting Agreement",
"Registration Rights Agreement",
"Leak-Out Agreement",
"CURE Pharmaceutical Closes $10 Million Financing - Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline - OXNARD, Calif. -- November 2, 2020 -- CURE Pharmaceutical Holdings , a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced that it has received the first tranche of $4 million of a committed financing of $10 million, after original issue discounts, through the issuance of convertible notes . Axiom Capital Management, Inc. acted as the sole placement agent) in the transaction. CURE may repay the obligations of the Notes in cash only, or the Notes may be converted upon election of the investor at a fixe..."
10/29/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/22/2020 8-K Termination of a Material Definitive Agreement
10/05/2020 8-K Quarterly results
09/30/2020 8-K Quarterly results
09/29/2020 8-K Quarterly results
09/24/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
06/09/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Amendment to Warrants to Purchase Common Stock",
"Release, Waiver and Amendment"
05/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Company webpage at http://bit.ly/curecoeptisupdate"
12/31/2019 8-K/A Quarterly results
11/21/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors"
11/14/2019 8-K Quarterly results
10/04/2019 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Plan of Conversion",
"Certificate of Conversion, as filed with the Secretary of State of Delaware on September 30, 2019",
"Certificate of Incorporation, as amended and restated, and as filed with the Secretary of State of Delaware on October 3, 2019",
"Delaware Bylaws",
"Articles of Conversion, as filed with the Secretary of State of Nevada on September 27, 2019"
08/08/2019 8-K Submission of Matters to a Vote of Security Holders
05/20/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement",
"CURE Pharmaceutical Expands Leadership Team with Key New Hires"
05/14/2019 8-K Appointed a new director
Docs: "CURE Pharmaceutical Closes Acquisition Of Privately-Held Chemistry Holdings Inc."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy